NYSEAMERICAN:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $0.19 -0.01 (-4.20%) (As of 07/3/2024 09:05 PM ET) Add Compare Share Share Today's Range$0.19▼$0.2150-Day Range N/A52-Week Range$0.14▼$13.79Volume458,800 shsAverage Volume1.12 million shsMarket Capitalization$9.87 millionP/E RatioN/ADividend YieldN/APrice Target$1.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Calidi Biotherapeutics alerts: Email Address Calidi Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside759.5% Upside$1.67 Price TargetShort InterestHealthy1.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.37) to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCalidi Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalidi Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Calidi Biotherapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.68% of the outstanding shares of Calidi Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently decreased by 16.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDI. Previous Next 2.6 News and Social Media Coverage News SentimentCalidi Biotherapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for CLDI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows4 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders34.50% of the stock of Calidi Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($0.37) to ($0.08) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Calidi Biotherapeutics Stock (NYSEAMERICAN:CLDI)Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Read More CLDI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDI Stock News HeadlinesJune 27, 2024 | americanbankingnews.comCalidi Biotherapeutics (NYSEAMERICAN:CLDI) Coverage Initiated by Analysts at LADENBURG THALM/SH SHJune 11, 2024 | businesswire.comCalidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13July 5, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…June 10, 2024 | businesswire.comCalidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsJune 3, 2024 | businesswire.comCalidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingMay 31, 2024 | businesswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsMay 17, 2024 | finanznachrichten.deCalidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone Show on Bloomberg TVMay 15, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024July 5, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…May 14, 2024 | businesswire.comCalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 1, 2024 | businesswire.comCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingApril 23, 2024 | finance.yahoo.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24April 23, 2024 | businesswire.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24April 19, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingApril 16, 2024 | msn.comWhy Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%April 16, 2024 | investorplace.comWhy Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?April 16, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingApril 9, 2024 | finance.yahoo.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024April 9, 2024 | businesswire.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024March 16, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023March 15, 2024 | businesswire.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsMarch 11, 2024 | businesswire.comCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerFebruary 12, 2024 | finance.yahoo.comCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceFebruary 8, 2024 | msn.comCalidi Biotherapeutics Shares Informal Financial UpdateFebruary 2, 2024 | msn.comCalidi Biotherapeutics Conducts Private Equity SaleJanuary 9, 2024 | uk.finance.yahoo.comCalidi Biotherapeutics, Inc. (CLDI)January 8, 2024 | finance.yahoo.comCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardSee More Headlines Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:CLDI CUSIPN/A CIKN/A Webcalidibio.com Phone858-794-9600FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Target$1.67 High Stock Price Target$2.00 Low Stock Price Target$1.00 Potential Upside/Downside+759.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,220,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-149.86% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual Sales$50,000.00 Price / Sales197.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.23) per share Price / Book-0.84Miscellaneous Outstanding Shares50,920,000Free Float33,355,000Market Cap$9.87 million OptionableNot Optionable Beta0.64 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Allan J. Camaisa (Age 63)CEO & Chairman of the Board Comp: $306.18kMs. Wendy Pizarro Campbell Esq. (Age 52)Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary Comp: $295.4kDr. Boris Minev M.D. (Age 60)Ph.D., President of Medical & Scientific Affairs and Interim Chief Medical Officer Comp: $400.1kMr. Andrew C. Jackson (Age 55)Chief Financial Officer Dr. Amish Patel Ph.D. (Age 47)Senior Vice President of Technical Operations Mr. Stephen Thesing (Age 58)Chief Business Officer More ExecutivesKey CompetitorsCurisNASDAQ:CRISEstrella ImmunopharmaNASDAQ:ESLAIN8bioNASDAQ:INABCyclo TherapeuticsNASDAQ:CYTHSurrozenNASDAQ:SRZNView All CompetitorsInstitutional OwnershipApollo Management Holdings L.P.Bought 125,000 shares on 5/16/2024Ownership: 0.352%Magnetar Financial LLCBought 63,132 shares on 5/15/2024Ownership: 0.178%Evermay Wealth Management LLCBought 63,416 shares on 5/14/2024Ownership: 0.178%Spectrum Asset Management Inc. NB CA Bought 166,494 shares on 4/23/2024Ownership: 0.468%View All Institutional Transactions CLDI Stock Analysis - Frequently Asked Questions Should I buy or sell Calidi Biotherapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calidi Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLDI shares. View CLDI analyst ratings or view top-rated stocks. What is Calidi Biotherapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 12-month price objectives for Calidi Biotherapeutics' stock. Their CLDI share price targets range from $1.00 to $2.00. On average, they predict the company's stock price to reach $1.67 in the next year. This suggests a possible upside of 759.5% from the stock's current price. View analysts price targets for CLDI or view top-rated stocks among Wall Street analysts. Are investors shorting Calidi Biotherapeutics? Calidi Biotherapeutics saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 857,800 shares, a drop of 16.7% from the May 31st total of 1,030,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 0.4 days. View Calidi Biotherapeutics' Short Interest. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.07. How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:CLDI) was last updated on 7/5/2024 by MarketBeat.com Staff From Our Partners1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthles...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts